NCT06644027Not yet recruitingNot Applicable
Effect of Different Types of Disposable Absorbent Sheets on the Local Skin Microclimate and Incidence of Incontinence-associated Dermatitis in Patients With Incontinence in the ICU: a Multicenter Randomized Controlled Trial
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Sir Run Run Shaw Hospital
- Enrollment
- 125
- Primary Endpoint
- Incidence of IAD
Study Overview
Brief Summary
To explore the feasibility of Jefcare Sterile Medical Sheets in preventing incontinence-associated dermatitis and maintaining a stable local skin microclimate in adult patients in the intensive care unit.
Detailed Description
Jefcare Sterile Medical Sheet is an incontinence care product designed by researchers following the Expert consensus on the clinical application of disposable absorbent care products for adults with incontinence. The product has good laboratory test indicators and has the potential to prevent incontinence-associated dermatitis and maintain the stability of the local skin microclimate. Still, there is a lack of high-quality clinical studies.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- None
Masking Description
Wound Ostomy and Continence Specialist Nurses and Dermatologists; laboratory technician
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Intensive care unit incontinent patients (incontinence time ≥2 days)
- •Age ≥18 years
- •patients at high risk of IAD (Perineal Assessment Tool ≥ 7)
- •Voluntarily participate in the study and sign an informed consent form. If the subject is unable to read and sign the informed consent form due to incapacitation or other reasons, their guardian is required to represent the informed process and sign the informed consent form. If the subject is unable to read the informed consent form (e.g., illiterate subjects), a witness will be required to witness the informed process and sign the informed consent form.
Exclusion Criteria
- •Patients who have developed IAD
- •Expected subsequent stay in the intensive care unit <5 days
- •Use of nappies, pull-ups, incontinence pads, etc.
- •Simple urinary incontinence with indwelling catheterization, external urinary bag without leakage; simple fecal incontinence with built-in drainage device, external ostomy bag, OB tampon without leakage; double incontinence with indwelling catheterization, external urinary bag, built-in drainage device, external ostomy bag, OB tampon without leakage.
- •The IAD may affect the skin area within the scope of the disease that affects the IAD judgment.
- •The IAD may affect the skin area within the scope of the skin breaks, infection
- •Patients who are not suitable for turning and cannot tolerate the side-lying position.
- •Patients with known allergies or keloid scarring
- •Women who are known to be pregnant or breastfeeding or who are planning to have a baby during the study period.
- •Patients who have participated in a clinical trial of another drug or medical device within 3 months.
- •Patients who, in the opinion of the investigator, are not suitable for participation in this clinical trial.
Outcomes
Primary Outcomes
Incidence of IAD
Time Frame: Follow-up on Day 2, Day 3, Day 4, and Day 5 of the intervention until the start of the IAD/end of the study i.e. day 5 of the intervention.
incidence of IAD = number of cases of patients with IAD in the group/total number of patients in the group × 100%.
Secondary Outcomes
- The skin microclimate and skin barrier function(Total 2 times. 1 prior to intervention, 1 on occurrence of IAD or end of the study i.e. day 5 of the intervention.)
- The time of IAD occurrence(Follow-up on Day 2, Day 3, Day 4, and Day 5 of the intervention until the start of the IAD/end of the study i.e. day 5 of the intervention.)
- The site and severity of IAD occurrence(Follow-up on Day 2, Day 3, Day 4, and Day 5 of the intervention until the start of the IAD/end of the study i.e. day 5 of the intervention)
- Date of faecal incontinence (post-intervention);Mean number of faecal incontinence per day (post-intervention).(The average number of medical sheets used per day:Follow-up on Day 2, Day 3, Day 4, and Day 5 of the intervention until the start of the IAD/end of the study i.e. day 5 of the intervention.)
- Average daily cost-effectiveness of medical sheets.(The average number of medical sheets used per day:Follow-up on Day 2, Day 3, Day 4, and Day 5 of the intervention until the start of the IAD/end of the study i.e. day 5 of the intervention.)
- Mycological examination(Total 2 times. 1 prior to intervention, 1 on occurrence of IAD or end of study i.e. day 5 of the intervention.)
Investigators
Similar Trials
Completed
Not Applicable
Prevention of Incontinence-associated Dermatitis and Maintenance of Local Skin MicroclimateIncontinence-associated DermatitisNCT06509932Sir Run Run Shaw Hospital40
Completed
Not Applicable
Continence Pessary Versus Disposable Intravaginal Device TrialFemale Stress IncontinenceNCT03174431Ohio State University50
Completed
Not Applicable
Oral Hygiene Tools for Biofilm Removal Around ImplantsHealthyHygieneBiofilm RemovalNCT06697210Universitat Internacional de Catalunya120
Completed
Not Applicable
Effectiveness of a new absorbent pad on incontinence-associated dermatitis in older adult womedisuse syndromeJPRN-UMIN000006188Department of Gerontological Nursing/Wound Care Management, Graduate School of Medicine, The University of Tokyo60
Unknown
Not Applicable
Effectiveness of PeeRelease - a Gel Absorbent Pad in Moderate to Severe Urinary IncontinenceUrinary IncontinenceNCT01066117Tisteron Ltd.90